{
    "nct_id": "NCT00420420",
    "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2015-01-28",
    "description_brief": "The purpose of this study is to test the efficacy and safety of an investigational medication for improving symptoms of Alzheimer's Disease. Subjects will receive either active medication or placebo for 28 days. Tests of memory, concentration will be included. Safety will be monitored using routine clinical and laboratory tests.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "At Visit 1, patients were assessed using the protocol inclusion and exclusion criteria, then, if deemed eligible, patients were randomized at Visit 3.",
            "recruitmentDetails": "First Patient Dosed: 13 JAN 2007; Last Patient Last Treatment: 14 AUG 2008. 15 U.S. outpatient centers.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "MK0249 (5 mg)",
                    "description": "Patients were randomly assigned to 28 days of treatment with 5 mg MK-0249 taken orally daily (qd)."
                },
                {
                    "id": "FG001",
                    "title": "Placebo",
                    "description": "Patients were randomly assigned to 28 days of treatment with matching placebo taken orally daily (qd)."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "comment": "Number of patients randomized.",
                                    "numSubjects": "73"
                                },
                                {
                                    "groupId": "FG001",
                                    "comment": "Number of patients randomized.",
                                    "numSubjects": "71"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "comment": "One patient from the MK-0249 arm discontinued the trial due to an AE prior to receiving study drug.",
                                    "numSubjects": "65"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "67"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "8"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "4"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "5"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "3"
                                }
                            ]
                        },
                        {
                            "type": "Protocol Violation",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "sponsor decision (abnormal ECG @ screen)",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "MK0249 (5 mg)",
                    "description": "Patients were randomly assigned to 28 days of treatment with 5 mg MK-0249 taken orally daily (qd)."
                },
                {
                    "id": "BG001",
                    "title": "Placebo",
                    "description": "Patients were randomly assigned to 28 days of treatment with matching placebo taken orally daily (qd)."
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "73"
                        },
                        {
                            "groupId": "BG001",
                            "value": "71"
                        },
                        {
                            "groupId": "BG002",
                            "value": "144"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "74.4",
                                            "spread": "6.91"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "73.7",
                                            "spread": "8.91"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "74.05",
                                            "spread": "7.91"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "43"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "36"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "79"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "30"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "35"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "65"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Week 4 Change From Baseline in Computerized Neuropsychological Test Battery (CNTB): Short CNTB Summary Score.",
                    "description": "The CNTB was used to evaluate cognitive function, as measured by the mean change from Baseline to Week 4 in the short CNTB summary score. The short CNTB summary score was scored as the mean score across 5 modules: Word List Learning-Selective Reminding, Word List Learning-Delayed Recall, Simple Reaction Time, Choice Reaction Time, and Visual Memory subtests. The short CNTB summary score ranges from 0 to 100, with higher scores (and positive changes from baseline) indicating better performance.",
                    "populationDescription": "Full Analysis Set: All patients who were randomized, took at least one dose of study medication, and had at least one efficacy measurement at either Baseline, Week 2 or Week 4. Patients were counted in the treatment group to which they were randomized.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline and Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "MK0249 (5 mg)",
                            "description": "Patients were randomly assigned to 28 days of treatment with 5 mg MK-0249 taken orally daily (qd)."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Patients were randomly assigned to 28 days of treatment with matching placebo taken orally daily (qd)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "59"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "62"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.13",
                                            "spread": "0.61"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.76",
                                            "spread": "0.57"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "comparison at Week 4",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.283",
                            "pValueComment": "A longitudinal mixed model was used to compare groups, including factors for week, strata (MMSE score and concomitant AD therapy), treatment, and week-by-treatment interaction.",
                            "statisticalMethod": "Mixed Models Analysis",
                            "ciPctValue": "95"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Week 4 Change From Baseline in Cognition Summary Score (CSS)",
                    "description": "The CSS was used to evaluate cognitive function as measured by the mean change from Baseline to Week 4 in the CSS total score. The CSS was derived from the correct sequence percentage from the Route Test and 6 of the CNTB scores (the CSS was scored as the mean of the 7 scores). CSS scores can range from 0 to 100, higher scores (and positive changes from baseline) indicate better performance.",
                    "populationDescription": "Full Analysis Set: All patients who were randomized, took at least one dose of study medication, and had at least one efficacy measurement at either Baseline, Week 2 or Week 4. Patients were counted in the treatment group to which they were randomized.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline and Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "MK0249 (5 mg)",
                            "description": "Patients were randomly assigned to 28 days of treatment with 5 mg MK-0249 taken orally daily (qd)."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Patients were randomly assigned to 28 days of treatment with matching placebo taken orally daily (qd)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "49"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "51"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.19",
                                            "spread": "0.75"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.19",
                                            "spread": "0.72"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "comparison at week 4",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.180",
                            "pValueComment": "A longitudinal mixed model was used to compare groups, including factors for week, strata (MMSE score and concomitant AD therapy), treatment, and week-by-treatment interaction.",
                            "statisticalMethod": "Mixed Models Analysis",
                            "ciPctValue": "95"
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Week 4 Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): ADAS-Cog Total Score",
                    "description": "The ADAS-Cog, scored as the total score of 11 tasks including mazes was used to evaluate cognitive function, as measured by the mean change from Baseline to Week 4 in the ADAS-Cog total score. The ADAS-Cog total score ranges from 0 to 70, with higher total scores indicating more impairment. Lower scores (and negative changes from Baseline) indicate better performance.",
                    "populationDescription": "Full Analysis Set: All patients who were randomized, took at least one dose of study medication, and had at least one efficacy measurement at either Baseline, Week 2 or Week 4. Patients were counted in the treatment group to which they were randomized.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline and Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "MK0249 (5 mg)",
                            "description": "Patients were randomly assigned to 28 days of treatment with 5 mg MK-0249 taken orally daily (qd)."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Patients were randomly assigned to 28 days of treatment with matching placebo taken orally daily (qd)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "70"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "68"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.42",
                                            "spread": "0.50"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.17",
                                            "spread": "0.49"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "comparison at Week 4",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.716",
                            "pValueComment": "A longitudinal mixed model was used to compare groups, including factors for week, strata (MMSE score and concomitant AD therapy), treatment, and week-by-treatment interaction.",
                            "statisticalMethod": "Mixed Models Analysis",
                            "ciPctValue": "95"
                        }
                    ]
                },
                {
                    "type": "OTHER_PRE_SPECIFIED",
                    "title": "Baseline: Short CNTB Summary Score.",
                    "description": "The CNTB was used to evaluate cognitive function, as measured by the mean change from Baseline to Week 4 in the short CNTB summary score. The short CNTB summary score was scored as the mean score across 5 modules: Word List Learning-Selective Reminding, Word List Learning-Delayed Recall, Simple Reaction Time, Choice Reaction Time, and Visual Memory subtests. The short CNTB summary score ranges from 0 to 100, with higher scores (and positive changes from baseline) indicating better performance.",
                    "populationDescription": "Full Analysis Set: All patients who were randomized, took at least one dose of study medication, and had at least one efficacy measurement at either Baseline, Week 2 or Week 4. Patients were counted in the treatment group to which they were randomized.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "MK0249 (5 mg)",
                            "description": "Patients were randomly assigned to 28 days of treatment with 5 mg MK-0249 taken orally daily (qd)."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Patients were randomly assigned to 28 days of treatment with matching placebo taken orally daily (qd)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "64"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "68"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "35.98",
                                            "spread": "5.72"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "36.23",
                                            "spread": "6.59"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "OTHER_PRE_SPECIFIED",
                    "title": "Baseline: ADAS-Cog Total Score",
                    "description": "The ADAS-Cog, scored as the total score of 11 tasks including mazes was used to evaluate cognitive function, as measured by the mean change from Baseline to Week 4 in the ADAS-Cog total score. The ADAS-Cog total score ranges from 0 to 70, with higher total scores indicating more impairment. Lower scores (and negative changes from Baseline) indicate better performance.",
                    "populationDescription": "Full Analysis Set: All patients who were randomized, took at least one dose of study medication, and had at least one efficacy measurement at either Baseline, Week 2 or Week 4. Patients were counted in the treatment group to which they were randomized.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "MK0249 (5 mg)",
                            "description": "Patients were randomly assigned to 28 days of treatment with 5 mg MK-0249 taken orally daily (qd)."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Patients were randomly assigned to 28 days of treatment with matching placebo taken orally daily (qd)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "73"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "70"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "19.08",
                                            "spread": "7.51"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "18.42",
                                            "spread": "7.32"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "OTHER_PRE_SPECIFIED",
                    "title": "Baseline: Cognition Summary Score (CSS)",
                    "description": "The CSS was used to evaluate cognitive function as measured by the mean change from Baseline to Week 4 in the CSS total score. The CSS was derived from the correct sequence percentage from the Route Test and 6 of the CNTB scores (the CSS was scored as the mean of the 7 scores). CSS scores can range from 0 to 100, higher scores (and positive changes from baseline) indicate better performance.",
                    "populationDescription": "Full Analysis Set: All patients who were randomized, took at least one dose of study medication, and had at least one efficacy measurement at either Baseline, Week 2 or Week 4. Patients were counted in the treatment group to which they were randomized.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "MK0249 (5 mg)",
                            "description": "Patients were randomly assigned to 28 days of treatment with 5 mg MK-0249 taken orally daily (qd)."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Patients were randomly assigned to 28 days of treatment with matching placebo taken orally daily (qd)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "56"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "57"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "42.31",
                                            "spread": "7.35"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "43.79",
                                            "spread": "7.32"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "2",
            "timeFrame": "Patients were assessed for AEs from Visit 2 (Day 0) Baseline through Visit 8 (Day 43) Post-Study Safety Visit.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "MK0249 (5 mg)",
                    "description": "Patients were randomly assigned to 28 days of treatment with 5 mg MK-0249 taken orally daily (qd).",
                    "seriousNumAffected": 3,
                    "seriousNumAtRisk": 73,
                    "otherNumAffected": 29,
                    "otherNumAtRisk": 73
                },
                {
                    "id": "EG001",
                    "title": "Placebo",
                    "description": "Patients were randomly assigned to 28 days of treatment with matching placebo taken orally daily (qd).",
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 70,
                    "otherNumAffected": 9,
                    "otherNumAtRisk": 70
                }
            ],
            "seriousEvents": [
                {
                    "term": "Accidental Overdose",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Hip fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Basal cell carcinoma",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Lung infiltration",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Diarrhoea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Dry mouth",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Dyspepsia",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Stomach discomfort",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Nasopharyngitis",
                    "organSystem": "Infections and infestations",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Urinary tract infection",
                    "organSystem": "Infections and infestations",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Excoriation",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 3,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Electrocardiogram QT prolonged",
                    "organSystem": "Investigations",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Arthralgia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Muscle spasms",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 70
                        }
                    ]
                },
                {
                    "term": "Insomnia",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 73
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 70
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."
            },
            "pointOfContact": {
                "title": "Senior Vice President, Global Clinical Development",
                "organization": "Merck Sharp & Dohme Corp.",
                "email": "ClinicalTrialsDisclosure@merck.com",
                "phone": "1-800-672-6372"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "MK-0249 (MK-0249) \u2014 small-molecule histamine H3 receptor inverse agonist (investigational; used 5 mg daily in the AD trial)."
    ],
    "placebo": [
        "Placebo (unspecified)"
    ],
    "explanation_target": [
        "Reason: The trial tests MK-0249 for symptomatic improvement of memory and concentration over 28 days (randomized, double-blind, placebo-controlled), indicating a symptomatic/cognitive aim rather than disease modification. \ue200cite\ue202turn0search0\ue201",
        "Act: MK-0249 is a small-molecule histamine H3 receptor inverse agonist (mechanism aimed at enhancing cognition via modulation of neurotransmitter release), so it is not a biologic nor a small molecule that targets core AD pathology (amyloid or tau). \ue200cite\ue202turn0search3\ue202turn0search2\ue201",
        "Act (trial details): The trial (Phase 2, N=144) gave MK-0249 two 2.5 mg capsules daily for 28 days versus placebo and measured cognitive tests (memory, concentration). \ue200cite\ue202turn0search0\ue201",
        "Evidence: The published pilot randomized controlled study reported no significant differences versus placebo on primary cognitive endpoints after 4 weeks, confirming the agent was evaluated as a symptomatic cognitive enhancer. \ue200cite\ue202turn0search3\ue202turn0search2\ue201",
        "Reflect: By the provided category definitions, this fits 'Cognitive enhancer' \u2014 a small-molecule symptomatic cognitive treatment (H3 inverse agonist) rather than a disease-targeted biologic or pathology-directed small molecule. No substantial ambiguity remains from the description or the literature reviewed. Sources consulted: clinical trial registry record (NCT00420420), PubMed pilot RCT (MK-0249 in AD), and drug/compound summary (NCATS/drugs). \ue200cite\ue202turn0search0\ue202turn0search3\ue202turn0search2\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests MK-0249, a small-molecule histamine H3 receptor inverse agonist, given as a symptomatic/cognitive enhancer to improve memory and concentration rather than targeting core AD pathology (amyloid or tau). \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Act: MK-0249\u2019s mechanism\u2014H3 receptor inverse agonism\u2014modulates release of neurotransmitters (histamine, acetylcholine, norepinephrine, dopamine) to enhance cognition, which maps to CADRO category D (Neurotransmitter Receptors). The Alzheimer's pilot RCT (4 weeks, n=144) evaluated cognitive endpoints and found no significant benefit versus placebo, confirming its symptomatic neurotransmitter-targeted use. \ue200cite\ue202turn0search6\ue202turn0search0\ue201",
        "Reflect: Classification as D) Neurotransmitter Receptors is the most specific fit because the drug acts on a neurotransmitter receptor (histamine H3) to produce symptomatic cognitive effects, not disease-modifying pathology (amyloid/tau/inflammation/etc.). There is no indication of multi-target disease-modifying intent or a non-therapeutic diagnostic focus, so 'D' is appropriate. \ue200cite\ue202turn0search4\ue202turn0search0\ue201",
        "Web search results (sources consulted): PubMed trial report of MK-0249 in AD (pilot RCT; cognition endpoints, no significant benefit). \ue200cite\ue202turn0search0\ue201; Review/discovery paper on H3 antagonists for cognitive disorders describing mechanism (neurotransmitter release modulation). \ue200cite\ue202turn0search6\ue201; Chemical/compound entry listing MK-0249 as a histamine H3 receptor inverse agonist. \ue200cite\ue202turn0search4\ue201"
    ]
}